semaglutide vs tirzepatide hair loss GLP-1 receptor agonists (semaglutide, tirzepatide) are associated with a small but real increase in shedding. In most cases, this represents telogen effluvium driven by rapid weight loss, not direct follicular toxicity Hair Loss Due to GLP-1:

In the STEP 1 trial published in the New England Journal of Medicine (2021), participants receiving semaglutide 2.4 mg weekly achieved an average weight loss of approximately 15% of body weight over 68 weeks, compared to 2.4% with placebo

If it does not, the most defensible general approach is cold-chain handling: freezer storage for long-term dry powder, refrigerator storage for short-term reconstituted solution, and no casual room-temperature storage after mixing

10.1016/S0735-1097(99)00216-8 J Am Coll Cardiol

ZhangJ.XieX

In placebo-controlled trials , only 0.2% of the participants using Ozempic experienced injection site reactions

* No interrumpir el tratamiento sin consultar: Los pacientes no deben interrumpir el tratamiento con GLP-1 RA por su cuenta